Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

412 results
Display

Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis

Kim SC, Lee WH, Kim SH, Abdulkhayevich AA, Park JW, Kim YM, Moon KH, Lee SH, Park S

Purpose: This study aimed to confirm the association between developmentally regulated GTP-binding protein 2 (DRG2) expression and docetaxel-induced apoptosis and to determine whether prostate cancer responses to docetaxel treatment differ...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study

Rakauskas A, Tawadros T, Lucca I, Herrera F, Bourhis J, Burruni R, Gomes MN, Codeluppi C, Jolliet L, Rosa SL, Meuwly JY, Jichlinski P, Berthold D, Valerio M

Purpose: To compare the clinical outcome of males with low-risk and favorable intermediate-risk prostate cancer managed within a standardized modern protocol of active surveillance. Materials and Methods: This was a prospective...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The presence of prostate-specific antigen checked more than 1 year before diagnostic biopsy is an independent prognostic factor in patients undergoing radical prostatectomy

Park SG, Shim KH, Choo SH, Kim SJ, Kim SI

Purpose: In large scale prospective studies, prostate-specific antigen (PSA)-screening not only decreased prostate cancer mortality, but also reduced biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP). We investigated the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prostate Imaging-Reporting and Data System: Comparison of the Diagnostic Performance between Version 2.0 and 2.1 for Prostatic Peripheral Zone

Kim HS, Kwon GY, Kim MJ, Park SY

Objective: To compare the diagnostic performance between Prostate Imaging-Reporting and Data System version 2.0 (PIRADSv2.0) and version 2.1 (PI-RADSv2.1) for clinically significant prostate cancer (csPCa) in the peripheral zone (PZ). Materials...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multiparametric MRI in Active Surveillance of Prostate Cancer: An Overview and a Practical Approach

Lee CH, Tan TW, Tan CH

MRI has become important for the detection of prostate cancer. MRI-guided biopsy is superior to conventional systematic biopsy in patients suspected with prostate cancer. MRI is also increasingly used for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cardiovascular Risks of Androgen Deprivation Therapy for Prostate Cancer

Corona G, Filippi S, Bianchi N, Dicuio M, Rastrelli G, Concetti S, Sforza A, Maggi M

Androgen deprivation therapy (ADT) is the gold standard treatment in patients with locally advanced or metastatic prostate cancer (PC). Emerging evidence has documented a tight association between ADT and body...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dose-volume histogram parameters and patient-reported EPIC-Bowel domain in prostate cancer proton therapy

Bulman GF, Bhangoo RS, DeWees TA, Petersen MM, Thorpe CS, Wong WW, Rwigema JCM, Daniels TB, Keole SR, Schild SE, Vargas CE

Purpose: To analyze rectal dose and changes in quality of life (QOL) measured with the Expanded Prostate and Cancer Index Composite (EPIC) bowel domain in patients being treated for prostate...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Outcome and Safety of Re-challenge Lutetium-177 PSMA (177Lu-PSMA) Therapy with Low-Dose Docetaxel as a Radiosensitizer—a Promising Combination in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): a Case Report

Maharaj M, Heslop L, Govender T, Korowlay N, Singh A, Choudhary P, Sathekge M

Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (PSMA-RLT) with lutetium-177 ( 177Lu-PSMA) has been used in metastatic castrate-resistant prostate cancer (mCRPC), and retrospective data have shown this therapy to be favourably...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Lower Urinary Tract Symptoms in Prostate Cancer Patients Treated With Radiation Therapy: Past and Present

Kwon WA, Lee SY, Jeong TY, Moon HS

The incidence of prostate cancer (PCa) is increasing concomitantly with population aging. Accordingly, interest in radiation therapy (RT) and the frequency of RT are also increasing. The types of RT...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk of second cancer among young prostate cancer survivors

Zhang H, Yu A, Baran A, Messing E

Purpose: About 40% of men diagnosed with prostate cancer (Pca) are
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Predictive Factors of De Novo Overactive Bladder After Radical Prostatectomy in Patients With Clinically Localized Prostate Cancer: A Prospective Observational Study

Lee JN, Kim SW, Byeon KH, Chung JW, Ha YS, Choi SH, Kim BS, Kim HT, Kim TH, Yoo ES, Kwon TG

Purpose: To evaluate the incidence of de novo overactive bladder (OAB) and the factors related to its occurrence following radical prostatectomy (RP) in patients with clinically localized prostate cancer (PCa). Materials...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Utility of Next-Generation Sequencing for Deciphering Intratumor Heterogeneity in Prostate Cancer

Joung JG, Park JY, Yang SY, Jeong J

Prostate cancer has long been considered a disease with a heterogeneous phenotype. The intratumor heterogeneity (ITH) may affect diverse phenotypes such as treatment response, drug resistance, and overall clinical outcomes....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
An Update of Gonadotropin-Releasing Hormone Antagonists in the Treatment of Advanced Prostate Cancer

Hong JH

For decades, androgen deprivation therapy (ADT) was the cornerstone treatment for advanced prostate cancer. ADT using gonadotropin-releasing hormone (GnRH) agonist or antagonist acts by blocking the hypothalamic-pituitary-gonadal system with different...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Role of Nkx3.1 in Cancers and Stemness

Antao AM, Ramakrishna S, Kim KS

The well-known androgen-regulated homeobox gene, NKX3.1, is located on the short arm of chromosome 8. It is the first known prostate epithelium-specific marker, and is a transcription factor involved in...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance

Salguero J, Gómez-Gómez E, Valero-Rosa J, Carrasco-Valiente J, Mesa J, Martin C, Campos-Hernández JP, Rubio JM, López D, Requena MJ

Objective: To evaluate the impact of multiparametric magnetic resonance imaging (mpMRI) before confirmatory prostate biopsy in patients under active surveillance (AS). Materials and Methods: This retrospective study included 170 patients with...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients

Kim SH, Kwon WA, Joung JY

Purpose: We evaluated the impact of benign prostatic hyperplasia (BPH) and prostatitis on the risk of prostate cancer (PCa) in patients using nationally representative data of the Korean population from...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Serum Testosterone Level as Possible Predictive Marker for Prognosis in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide

An DH, Kim H, Lee D, Jeong IG, You D, Hong JH, Kim CS, Ahn H

Purpose: This study aimed to evaluate the impact of serum testosterone level before enzalutamide treatment in metastatic castration-resistant prostate cancer (mCRPC) for antitumor outcomes. Materials and Methods: Single-center, retrospective study including...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Real-World Experience of Single-Center, Retrospective Study of the Prognostic Effect of Secondary Hormone Agent on Survival in Patients With Hormone-Refractory Metastatic Prostate Cancer

Kim SH, Lee DE, Seo HK, Chung J, Joung JY

Purpose: This study aimed to analyze the overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with either combination or only secondary hormone therapy (2ndHTx) or docetaxel...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Expert Group Consensus Opinion on Prostate Cancer Diagnosis and Management in India: Part 2 of 2

Ghose A, Khochikar M, Sabnis R, Parmar NM, Purkait I

With limited/no guidelines on prostate cancer (PCa) diagnosis and management currently in India, this consensus statement has been developed to evaluate Indian literature and current clinical practices to assist healthcare...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Synergistic anticancer activity of resveratrol in combination with docetaxel in prostate carcinoma cells

Lee SH, Lee YJ

BACKGROUND/OBJECTIVES: The study was conducted to investigate the efficacy of the combination treatment of phytochemical resveratrol and the anticancer drug docetaxel (DTX) on prostate carcinoma LNCaP cells, including factors related...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr